Search

Your search keyword '"Okazaki, Katsunori"' showing total 12 results
Start Over Author "Okazaki, Katsunori" Publication Year Range Last 10 years
12 results on '"Okazaki, Katsunori"'

1. A novel nairovirus associated with acute febrile illness in Hokkaido, Japan

Author

Kodama, Fumihiro, Yamaguchi, Hiroki, Park, Eunsil, Tatemoto, Kango, Sashika, Mariko, Nakao, Ryo, Terauchi, Yurino, Mizuma, Keita, Orba, Yasuko, Kariwa, Hiroaki, Hagiwara, Katsuro, Okazaki, Katsunori, Goto, Akiko, Komagome, Rika, Miyoshi, Masahiro, Ito, Takuya, Yamano, Kimiaki, Yoshii, Kentaro, Funaki, Chiaki, Ishizuka, Mariko, Shigeno, Asako, Itakura, Yukari, Bell-Sakyi, Lesley, Edagawa, Shunji, Nagasaka, Atsushi, Sakoda, Yoshihiro, Sawa, Hirofumi, Maeda, Ken, Saijo, Masayuki, and Matsuno, Keita

Published
2021
Full Text
View/download PDF

4. A novel nairovirus associated with acute febrile illness in Hokkaido, Japan

Author

Kodama, Fumihiro, Yamaguchi, Hiroki, Park, Eunsil, Tatemoto, Kango, Sashika, Mariko, Nakao, Ryo, Terauchi, Yurino, Mizuma, Keita, Orba, Yasuko, Kariwa, Hiroaki, Hagiwara, Katsuro, Okazaki, Katsunori, Goto, Akiko, Komagome, Rika, Miyoshi, Masahiro, Ito, Takuya, Yamano, Kimiaki, Yoshii, Kentaro, Funaki, Chiaki, Ishizuka, Mariko, Shigeno, Asako, Itakura, Yukari, Bell-Sakyi, Lesley, Edagawa, Shunji, Nagasaka, Atsushi, Sakoda, Yoshihiro, Sawa, Hirofumi, Maeda, Ken, Saijo, Masayuki, Matsuno, Keita, Kodama, Fumihiro, Yamaguchi, Hiroki, Park, Eunsil, Tatemoto, Kango, Sashika, Mariko, Nakao, Ryo, Terauchi, Yurino, Mizuma, Keita, Orba, Yasuko, Kariwa, Hiroaki, Hagiwara, Katsuro, Okazaki, Katsunori, Goto, Akiko, Komagome, Rika, Miyoshi, Masahiro, Ito, Takuya, Yamano, Kimiaki, Yoshii, Kentaro, Funaki, Chiaki, Ishizuka, Mariko, Shigeno, Asako, Itakura, Yukari, Bell-Sakyi, Lesley, Edagawa, Shunji, Nagasaka, Atsushi, Sakoda, Yoshihiro, Sawa, Hirofumi, Maeda, Ken, Saijo, Masayuki, and Matsuno, Keita

Abstract

type:Article, The increasing burden of tick-borne orthonairovirus infections, such as Crimean-Congo hemorrhagic fever, is becoming a global concern for public health. In the present study, we identify a novel orthonairovirus, designated Yezo virus (YEZV), from two patients showing acute febrile illness with thrombocytopenia and leukopenia after tick bite in Hokkaido, Japan, in 2019 and 2020, respectively. YEZV is phylogenetically grouped with Sulina virus detected in Ixodes ricinus ticks in Romania. YEZV infection has been confirmed in seven patients from 2014–2020, four of whom were co-infected with Borrelia spp. Antibodies to YEZV are found in wild deer and raccoons, and YEZV RNAs have been detected in ticks from Hokkaido. In this work, we demonstrate that YEZV is highly likely to be the causative pathogen of febrile illness, representing the first report of an endemic infection associated with an orthonairovirus potentially transmitted by ticks in Japan.

Published
2023

11. Isolation of a sp. nov. Ljungan virus from wild birds in Japan

Author

Mitake, Hiromichi, primary, Fujii, Yuji, additional, Nagai, Makoto, additional, Ito, Naoto, additional, Okadera, Kota, additional, Okada, Kazuma, additional, Nakagawa, Kento, additional, Kishimoto, Mai, additional, Mizutani, Tetsuya, additional, Okazaki, Katsunori, additional, Sakoda, Yoshihiro, additional, Takada, Ayato, additional, and Sugiyama, Makoto, additional

Published
2016
Full Text
View/download PDF

12. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.

Author

Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, and Boku N

Subjects
Adult, Aged, Analgesics, Opioid therapeutic use, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Japan, Male, Middle Aged, Naltrexone administration & dosage, Neoplasms diagnosis, Neoplasms epidemiology, Opioid-Related Disorders diagnosis, Opioid-Related Disorders drug therapy, Pain Management methods, Reference Values, Risk Assessment, Severity of Illness Index, Treatment Outcome, Analgesics, Opioid adverse effects, Constipation chemically induced, Constipation drug therapy, Naltrexone analogs & derivatives, Neoplasms drug therapy
Abstract

Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy and safety of a peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), for OIC, specifically in patients with cancer. Patients and Methods This phase III trial consisted of a 2-week, randomized, double-blind, placebo-controlled study (COMPOSE-4) and an open-label, 12-week extension study (COMPOSE-5). In COMPOSE-4, eligible adults with OIC and cancer were randomly assigned on a 1:1 basis to receive once-daily oral naldemedine 0.2 mg or placebo. The primary end point was the proportion of spontaneous bowel movement (SBM) responders (≥ 3 SBMs/week and an increase of ≥ 1 SBM/week from baseline). The primary end point of COMPOSE-5 was safety. Results In COMPOSE-4, 193 eligible patients were randomly assigned to naldemedine (n = 97) or placebo (n = 96). The proportion of SBM responders in COMPOSE-4 was significantly greater with naldemedine than with placebo (71.1% [69 of 97 patients] v 34.4% [33 of 96 patients]; P < .0001). A greater change from baseline was observed with naldemedine than with placebo in the frequency of SBMs/week (5.16 v 1.54; P < .0001), SBMs with complete bowel evacuation/week (2.76 v 0.71; P < .0001), and SBMs without straining/week (3.85 v 1.17; P = .0005). In COMPOSE-4, more patients treated with naldemedine than with placebo reported treatment-emergent AEs (TEAEs) (44.3% [43 of 97 patients] v 26.0% [25 of 96 patients]; P = .01); in COMPOSE-5, 105 (80.2%) of 131 of patients reported TEAEs. Diarrhea was the most frequently reported TEAE in COMPOSE-4 (19.6% [19 of 97 patients] v 7.3% [seven of 96 patients] with naldemedine v placebo) and COMPOSE-5 (18.3% [24 of 131 patients] with naldemedine). Naldemedine was not associated with signs or symptoms of opioid withdrawal and had no notable impact on opioid-mediated analgesia. Conclusion Once-daily oral naldemedine 0.2 mg effectively treated OIC and was generally well tolerated in patients with OIC and cancer.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results